Donna Berry on Compliance to Oral Cancer Therapies

Article

Donna Berry, from Dana-Farber Cancer Institute, on Compliance to Oral Cancer Therapies.

Donna L. Berry, PhD, RN, AOCN, FAAN, Dana-Farber Cancer Institute, Director, The Phyllis F. Cantor Center for Nursing Research, Associate Professor of Medicine, Harvard Medical School, discusses the challenges and compliance issues that are associated with the use of oral therapies for cancer.

Oral cancer therapies are becoming more common, Berry suggests. Additionally, some of these agents have substantial side effects and because they are taken at home on a regular basis the side effects that occur cannot be observed by the treatment team.

If difficult side effects occur, such as skin rash or diarrhea, many patients may stop taking their medication without first consulting a physician. Inversely, if intolerable side effects do not occur they may take twice the recommended dose with the hope that it will work better. Additionally, if a dose is missed they may take a double dose the next day to compensate.

Inaccurate self-administration is one of the most difficult challenges faced when trying to manage oral cancer treatments.

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.

Recent Videos
2 experts are featured in this series.
2 experts are featured in this series.
Photo of a woman with brown hair and a floral blouse
Photo of a woman with a blue border around the image
2 experts are featured in this series.
2 experts are featured in this series.
Image of a woman with gray hair and glasses in front of a blue Oncology Nursing News background
Photo of a woman with blond wavy hair wearing a blazer in front of a blue Oncology Nursing News background
Photo of a woman with shoulder-length blond hair in front of an Oncology Nursing News backdrop
Image of a woman with white hair in front of an Oncology Nursing News blue background
Related Content